Cardiovascular diseases (CVDs) are the leading cause of death globally1
According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths1. Of these deaths, 85% were due to myocardial infarction or stroke1.
A CV event is a highly traumatic experience for patients and their families2. It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life3,4.
The need is clear: it is important to do more to prevent devastating cardiovascular events in very high-risk patients that cause personal, societal and economic trauma.
Reducing risk in very high-risk ASCVD patients requires a HOLISTIC APPROACH and control of all modifiable risk factors, including elevated low-density lipoprotein cholesterol (LDL-C)5.
Over 4 million deaths were attributed to elevated LDL-C in 20196,12. That's eight deaths per minute, and many of those could be prevented.
According to the 2019 ESC/EAS Guidelines for the management of dyslipidaemia and the 2023 ESC Guidelines for the management of CVD in patients with diabetes, all ASCVD patients without exceptions are classified as very high-risk and, as such, have very strict LDL-C targets:
<55 mg/dL (<1.4 mmol/L) AND ≥ 50% LDL-C reduction vs. baseline5,11.
Yet, less than one third of ASCVD patients had their LDL-C levels within target range, according to the multinational observational SANTORINI study7. The reasons behind that are numerous, with one of them certainly being underuse of lipid-lowering treatment (LLT), most notably - combined LLT in general and PCSK9 inhibitors in particular7.
Who are the very high-risk patients?
Meet Susan, 65
T2DM: from age 50 / LDL-C: 2.9 mmol/L (112 mg/dL) / BP: 130/80 mmHg / HbA1c: 7.0% / TGs: 165 mg/dL / BMI:
29 kg/m2
Complains of transient chest pain and shortness of breath while climbing stairs
Current medications:
Rosuvastatin 40 mg / ezetimibe 10 mg / telmisartan 80 mg / insulin glargine 300 units/mL / metformin 2000 mg / acetysalicylic acid 100 mg / liraglutide 1.2 mg
Patients with combined T2DM and CAD have a 28% higher risk of CV events* compared to those without T2DM8
*cardiovascular death, myocardial infarction or stroke
Meet Eric, 62
Smoker / LDL-C: 2.9 mmol/L (112 mg/dL) / BP: 140/80 mmHg / HbA1c: 5.0% / TGs: 140 mg/dL / BMI: 27 kg/m2
Complained of progressive persistent anginal symptoms, 12 months ago - CTA was performed, 55% obstruction of left anterior descending artery was found, subsequently - severe stenosis was confirmed during a cardiac catheterization, and elective PCI was performed
Current medications:
Rosuvastatin 40 mg / ezetimibe 10 mg / acetysalicylic acid 100 mg / clopidogrel 75 mg
Coronary artery disease (ischemic heart disease) is the leading cause of mortality worldwide, accounting for 16% of all deaths in 20199
Meet John, 60
Long-term smoker / LDL-C: 2.5 mmol/L (98 mg/dL) /
BP: 130/80 mmHg / T2DM: since age 48 / HbA1c: 7.5% / TGs: 167 mg/dL / BMI: 28 kg/m2
Complains of moderate pain in calves on exertion, which is relieved by rest
Current medications:
Atorvastatin 80 mg / ezetimibe 10 mg / insulin glargine 300 units/mL / metformin 2000 mg / acetysalicylic acid 100 mg / rivaroxaban 5 mg / liraglutide 1.2 mg
Patients with combined T2DM and PAD have a nearly 8x higher risk of CV events compared to those without either condition10
Time to Act Early. Time to Prevent The Event.
The healthcare community aims to help ASCVD patients avoid the trauma of a 1st event through effective LDL-C control and CV risk reduction
Abbreviations:
ASCVD - atherosclerotic cardiovascular disease, BMI - body mass index, BP - blood pressure, CAD - coronary artery disease, CTA - computed tomography angiography, CV- cardiovascular, CVD - cardiovascular disease, ESC - European Society of Cardiology, EAS - European Atherosclerosis Society, HbA1c - glycated haemoglobin, LDL-C - low density lipoprotein cholesterol, LLT - lipid-lowering treatment, PAD - peripheral artery disease, PCI - percutaneous coronary intervention, PSCK9i - proprotein convertase subtilisin/kexin type 9 inhibitor, T2DM - type 2 diabetes mellitus, TGs - triglycerides
References
1.World Health Organization. Cardiovascular Diseases. Cardiovascular diseases (CVDs) (who.int). Last accessed July 2024
2.Princip, M., Ledermann, K. & von Känel, R. Posttraumatic Stress Disorder as a Consequence of Acute Cardiovascular Disease. Curr Cardiol Rep 25, 455–465 (2023). https://doi.org/10.1007/s11886-023-01870-1
3.Kim J. Post-stroke mood and emotional disturbances: pharmacological therapy based on mechanisms. J Stroke. 2016 Sep; 18(3): 244-255. Published online 2016 Sep 30. doi: 10.5853/jos.2016.01144
4.Mollon L, Bhattacharjee S. Health related quality of life among myocardial infarction survivors in the United States: a propensity score matched analysis. Health Qual Life Outcomes. 2017 Dec 4;15(1):235. Health related quality of life among myocardial infarction survivors in the United States: a propensity score matched analysis | Health and Quality of Life Outcomes | Full Text (biomedcentral.com)
5.Marx N et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-4140. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - PubMed (nih.gov)
6.Mattiuzzi C, Sanchis-Gomar F, Lippi G. Worldwide burden of LDL cholesterol: Implications in cardiovascular disease. Nutr Metab Cardiovasc Dis. 2020;30(2):241-244. Worldwide burden of LDL cholesterol: Implications in cardiovascular disease - PubMed (nih.gov)
7.Ray KK, et al; SANTORINI Study Investigators. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023 Apr 5;29:100624.Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study - PubMed (nih.gov)
8.Mak KH, et al. CLARIFY Investigators. Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities - PubMed (nih.gov)
9.World Health Organization. The top 10 causes of death. 2020. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed: July 2024;
10.Saely CH, et al. Single and combined effects of peripheral artery disease and of type 2 diabetes mellitus on the risk of cardiovascular events: A prospective cohort study. Atherosclerosis. 2018 Dec;279:32-37; Single and combined effects of peripheral artery disease and of type 2 diabetes mellitus on the risk of cardiovascular events: A prospective cohort study - PubMed (nih.gov)
11.Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk | European Heart Journal | Oxford Academic (oup.com). Erratum in: Eur Heart J. 2020 Nov 21;41(44):4255. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk - PubMed (nih.gov)
12. Zheng J, Wang J, Zhang Y, Xia J, Guo H, Hu H, Shan P, Li T. The Global Burden of Diseases attributed to high low-density lipoprotein cholesterol for 1990 to 2019. Front Public Health. 2022 Aug 16;10:891829. The Global Burden of Diseases attributed to high low-density lipoprotein cholesterol from 1990 to 2019 - PubMed (nih.gov)
MAT-GLB-2403978 - 2.0-02/2025
License may vary from country to country, please refer to your local summary of product characteristics for further information.
